+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease

Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease

Pediatric Allergy and Immunology 19(2): 184-185

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054886828

Download citation: RISBibTeXText

PMID: 18257906

DOI: 10.1111/j.1399-3038.2007.00657.x

Related references

Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease. Pediatric Allergy and Immunology 19(2): 186-187, 2008

Treatment of Kawasaki disease using locally product intravenous immunoglobulin. Journal of the Medical Association of Thailand 86(Suppl. 3): S656-S660, 2003

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?. Korean Circulation Journal 47(2): 179-181, 2017

Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. Journal of Pediatrics 163(2): 521-526, 2013

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease. Pediatric Rheumatology Online Journal 9: 28, 2011

Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial. Bmc Pediatrics 18(1): 200, 2018

Treatment of a patient with Kawasaki disease associated with selective IgA deficiency by continuous infusion of cyclosporine A without intravenous immunoglobulin. Turkish Journal of Pediatrics 58(6): 666-668, 2016

Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. American Journal of Hematology 63(3): 160-161, 2000

Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. Journal of Investigational Allergology and Clinical Immunology 20(5): 413-418, 2010

Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease. International Archives of Allergy and Immunology 164(2): 83-88, 2014

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment. Human Molecular Genetics 27(15): 2671-2677, 2018

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease. Korean Circulation Journal 48(1): 86-88, 2018

Intravenous immunoglobulin in kawasaki disease. Pediatric Research 24(5): 654, 1988

Immunoglobulin preparations affect hyponatremia in Kawasaki disease. European Journal of Pediatrics 169(8): 957-960, 2010

Intravenous immunoglobulin, pharmacogenomics, and Kawasaki disease. Journal of Microbiology Immunology and Infection 49(1): 1-7, 2016